Asset Protection for Peptide Founders: What to Consider as Your Business Scales

The peptide industry has created a new wave of founders. Some businesses that started small are now generating significant monthly revenue. Growth can happen quickly in this space, especially when demand is strong and operations can scale online. That kind of growth creates opportunity. It also creates risk. Many founders focus on building revenue, expanding […]
Buying a House in New York: The Ultimate Guide for First-Time Homebuyers

Buying your first home is an exciting milestone, but buying a house in New York comes with unique legal, financial, and logistical challenges. From competitive markets to state-specific closing costs and regulations, first-time buyers often find the process more complex than expected. At LumaLex Law, our real estate attorneys help clients navigate every stage of […]
The Truth Behind the “$1 Billion AI Telehealth Company”

A recent New York Times article tells a story that has gained a lot of attention. A founder builds a telehealth company from home. AI handles much of the work. The company reaches a billion-dollar valuation. It is a compelling narrative. It also leaves out important context. Stories like this tend to focus on speed […]
How Research-Use Peptide Companies Can Protect Their Assets in a High-Scrutiny Environment

The research-use peptide industry is changing. What was once a niche market is now attracting attention from regulators, payment processors, and competitors. As the industry grows, so does the level of scrutiny. For founders and operators, the key question is no longer whether risk exists. The real question is how well your business is structured […]
Legal Issues AI Technology Companies Must Address When Building and Scaling

Artificial intelligence is moving into every major industry. Companies are using AI to improve healthcare, automate finance, power marketing tools, and build new products at a pace that was not possible a few years ago. This speed creates opportunity, but it also creates legal risk. Many AI companies focus on product development, hiring engineers, and […]
Why Did Peptide Sciences Shut Down? What It May Mean for the Peptide Industry

In recent days, many businesses operating in the peptide markets have been asking the same question: “Why did Peptide Sciences shut down?” Peptide Sciences was widely viewed as one of the most visible companies selling research peptides online in the United States. Its website and brand were familiar to researchers, biohacking communities, and businesses following […]
Beyond the Sale: Alternative Lithotripsy Commercial Models That Can Reduce Stark Exposure

Lithotripsy equipment sellers see the same pattern again and again. Hospitals and ASCs want access to lithotripsy without spending hundreds of thousands of dollars upfront. They also want predictable scheduling, high uptime, and fewer operational headaches. That is why many companies now sell a turnkey service line, not just a machine. This shift creates a […]
AI Data Privacy Obligations: What Businesses Need to Know in 2026

Artificial intelligence is no longer experimental. It is embedded in customer analytics, hiring tools, fraud detection systems, health platforms, and enterprise automation. As widespread use accelerates, so do regulatory expectations. In 2026, AI data privacy obligations are no longer theoretical compliance concerns. They are active legal risks tied to enforcement actions, cross border investigations, and […]
RFK Jr., Peptides, and the FDA: Why Social Media Is Overhyping the Legal Reality

After recent comments by Robert F. Kennedy Jr. on the Joe Rogan Experience, social media lit up with claims that peptide regulation is about to change overnight. Posts began circulating that “14 peptides are coming off the FDA’s Category 2 list” and that compounding restrictions are about to disappear. Those claims are not supported by […]
Supreme Court Invalidates Certain Trump-Era Tariffs: Can Businesses Recover Paid Duties?

The Supreme Court recently issued a decision that has major implications for U.S. importers. The Court ruled that certain tariffs imposed during the Trump administration exceeded the authority granted by Congress. For companies that paid those duties, the practical question is immediate: If we paid these tariffs, can we get our money back? In some […]